SLC5A2 and Hypoglycemia: Insulin glargine and the SUs caused significantly higher rates of confirmed hypoglycemia when compared to SGLT2 inhibitors, DPP-4 inhibitors and placebo making them less attractive options for patients with Type 2 DM.